top
Search terms
Results 1 - 10 of 27 - ordered by :
Pages: 1 2 3
Transportation to primary percutaneous coronary intervention, compared with on-site fibrinolysis, is a strong independent predictor of functional status after myocardial infarction: 5-year follow-up of the PRAGUE-2 trial
Ehjacc

Aims: Subjective symptoms represent significant criteria of a patients health condition; therefore, we focused on the long-term prevalence of heart failure symptoms and angina pectoris after ...

European Heart Journal: Acute Cardiovascular Care, Original scientific papers, Dana Mocova Bilkova, Zuzana Motovska, Bohumir Prochazka, Ladislav Groch, Michael Zelizko, Michael Aschermann, Petr ...

Date : 01/06/2014
Optimal timing of initiation of oral P2Y12-receptor antagonist therapy in patients with non-ST elevation acute coronary syndromes. Lessons learnt from the ACCOAST-trial
Ehjacc

Optimal timing of initiation of oral P2Y12-receptor antagonist therapy in patients with non-ST elevation acute coronary syndromes. Ranking: 2015 SJR (SCImago Journal Rank) Score: 1.447 | 10/78 ...

European Heart Journal: Acute Cardiovascular Care, Clinical Practice/Education, Uwe Zeymer, Gilles Montalescot, Diego Ardissino, Leonardo Bolognese, Peter Clemmensen, Jean-Philippe Collet, Jose ...

Date : 28/04/2015
Optimal timing of initiation of oral P2Y12-receptor antagonist therapy in patients with non-ST elevation acute coronary syndromes. Lessons learnt from the ACCOAST-trial
Ehjacc

Optimal timing of initiation of oral P2Y12-receptor antagonist therapy in patients with non-ST elevation acute coronary syndromes. Ranking: 2015 SJR (SCImago Journal Rank) Score: 1.447 | 10/78 ...

European Heart Journal: Acute Cardiovascular Care, Clinical Practice/Education, Uwe Zeymer, Gilles Montalescot, Diego Ardissino, Leonardo Bolognese, Peter Clemmensen, Jean-Philippe Collet, Jose ...

Date : 28/04/2015
Optimal timing of initiation of oral P2Y12-receptor antagonist therapy in patients with non-ST elevation acute coronary syndromes. Lessons learnt from the ACCOAST-trial
Ehjacc

Optimal timing of initiation of oral P2Y12-receptor antagonist therapy in patients with non-ST elevation acute coronary syndromes. Email: zeymeru{at}klilu.de Abstract The optimal time-point of the ...

European Heart Journal: Acute Cardiovascular Care, Clinical Practice/Education, Uwe Zeymer, Gilles Montalescot, Diego Ardissino, Leonardo Bolognese, Peter Clemmensen, Jean-Philippe Collet, Jose ...

Date : 28/04/2015
Optimal timing of initiation of oral P2Y12-receptor antagonist therapy in patients with non-ST elevation acute coronary syndromes. Lessons learnt from the ACCOAST-trial
Ehjacc

Optimal timing of initiation of oral P2Y12-receptor antagonist therapy in patients with non-ST elevation acute coronary syndromes. Ranking: 2015 SJR (SCImago Journal Rank) Score: 1.447 | 10/78 ...

European Heart Journal: Acute Cardiovascular Care, Clinical Practice/Education, Uwe Zeymer, Gilles Montalescot, Diego Ardissino, Leonardo Bolognese, Peter Clemmensen, Jean-Philippe Collet, Jose ...

Date : 28/04/2015
Optimal timing of initiation of oral P2Y12-receptor antagonist therapy in patients with non-ST elevation acute coronary syndromes. Lessons learnt from the ACCOAST-trial
Ehjacc

Optimal timing of initiation of oral P2Y12-receptor antagonist therapy in patients with non-ST elevation acute coronary syndromes. Email: zeymeru{at}klilu.de Abstract The optimal time-point of the ...

European Heart Journal: Acute Cardiovascular Care, Clinical Practice/Education, Uwe Zeymer, Gilles Montalescot, Diego Ardissino, Leonardo Bolognese, Peter Clemmensen, Jean-Philippe Collet, Jose ...

Date : 28/04/2015
Optimal timing of initiation of oral P2Y12-receptor antagonist therapy in patients with non-ST elevation acute coronary syndromes. Lessons learnt from the ACCOAST-trial
Ehjacc

Optimal timing of initiation of oral P2Y12-receptor antagonist therapy in patients with non-ST elevation acute coronary syndromes. Email: zeymeru{at}klilu.de Abstract The optimal time-point of the ...

European Heart Journal: Acute Cardiovascular Care, Clinical Practice/Education, Uwe Zeymer, Gilles Montalescot, Diego Ardissino, Leonardo Bolognese, Peter Clemmensen, Jean-Philippe Collet, Jose ...

Date : 28/04/2015
Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial
Ehjacc

Aims: In the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38), prasugrel reduced the ...

European Heart Journal: Acute Cardiovascular Care, Original scientific papers, Stefano De Servi, Jochen Goedicke, Andreas Schirmer, Petr Widimsky

Date : 01/12/2014
Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial
Ehjacc

Aims: In the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38), prasugrel reduced the ...

European Heart Journal: Acute Cardiovascular Care, Original scientific papers, Stefano De Servi, Jochen Goedicke, Andreas Schirmer, Petr Widimsky

Date : 01/12/2014
Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial
Ehjacc

Aims: In the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38), prasugrel reduced the ...

European Heart Journal: Acute Cardiovascular Care, Original scientific papers, Stefano De Servi, Jochen Goedicke, Andreas Schirmer, Petr Widimsky

Date : 01/12/2014
SEE MORE